Clinical Rheumatology and Related Research
Online ISSN : 2189-0595
Print ISSN : 0914-8760
ISSN-L : 0914-8760
original article
A case of systemic lupus erythematosus with myelofibrosis improved by high-dose corticosteroid therapy
Hide Yoshida, Hirahito Endo, Junichi Tanaka, Nobuko Iizuka, Miho Kimura, Atsushi Hashimoto, Sumiaki Tanaka, Akira Ishikawa, Shunsei Hirohata, Hirobumi Kondo
Author information
JOURNAL FREE ACCESS

2008 Volume 20 Issue 4 Pages 302-309

Details
Abstract
    A woman of 50 years of age who had a 13-year history of hypothyroidism was diagnosed with systemic lupus erythematosus (SLE) with butterfly rash, leukopenia, positivity of antinuclear antibody, anti-DNA antibody and anti-Sm antibody. Two years later, she developed nephritis (WHO type IV) and remitted with corticosteroid pulse and intermittent intravenous cyclophosphamide pulse therapy (IVCY). Four years after the onset of SLE, she relapsed with proteinuria and leukopenia when she was taking 9 mg/day of prednisolone (PSL) but she stopped all the medication of her own accord. Four months passed without any therapy, she was admitted to our hospital with disturbance of consciousness and anasarca. Laboratory findings showed pancytopenia (WBC 1300/μl, RBC 233×10⁴/μl, Hb6.9g/dl, Plt3.6×10⁴/μl), aggravation of lupus nephritis and hypothyroidism. Chest X-ray and ultrasonography demonstrated pleural and pericardial effusion and the absence of hepatosplenomegaly. She was also diagnosed with myelofibrosis upon bone marrow inspection. Three instances of corticosteroid pulse therapy, oral corticosteroid (PSL was tapered from 50 mg/day) and supplement therapy of levothyroxine improved every symptom and pancytopenia. The second bone marrow biopsy showed reduced fibrosis and recovery of bone marrow cells. These findings implied the secondary myelofibrosis caused by SLE because the myelofibrosis came along with aggravation of SLE and corticosteroid therapy was effective. This is a rare case of SLE in which myelofibrosis improved by high-dose corticosteroid therapy, which was confirmed by bone marrow biopsy and suggests the pathogenic mechanisms for myelofibrosis.
Content from these authors
© 2008 The Japanese Society for Clinical Rheumatology and Related Research
Previous article Next article
feedback
Top